|
FDA Reviewers Cast Doubt on Eisai Leukemia Candidate Dacogen
Eisai’s cancer drug Dacogen failed to show benefit for acute myelogenous leukemia (AML) in adults 65 and older, FDA reviewers say in advance of a Thursday advisory committee meeting.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives